SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Kar SK, Choudhary P, Raje D, Bharti V. Indian J. Psychiatry 2024; 66(3): 311-312.

Copyright

(Copyright © 2024, Medknow Publications)

DOI

10.4103/indianjpsychiatry.indianjpsychiatry_823_23

PMID

39100119

PMCID

PMC11293285

Abstract

To the Editor,

Neuropsychological symptoms are common presentations in patients with traumatic brain injury (TBI) in the long run. The manifestations range from cognitive deficits to anxiety, depression, personality changes (impulsivity, irritability, apathy, lability of affect), suicidality, and several other behavioral changes that interfere with their socio-occupational functioning.[1,2] Treatment of the neuropsychological sequel of TBI is heterogeneous as concluded from the analysis of several randomized controlled trials.[3] In this case study, we highlight the role of multi-modal intervention (pharmacotherapy, transcranial random noise stimulation, and cognitive remediation) in the management of the cognitive and behavioral symptoms following TBI.

A 28-year-old man visited the neuro-psychiatric clinic due to persistent forgetfulness and increased irritability over the past 4 years. Initially, he suffered a head injury in December 2019 from a road traffic accident, resulting in hemorrhages on bilateral frontal lobes. After a right frontal craniotomy, he spent 38 days in a coma and showed disorientation upon regaining consciousness. Despite consultations with neurologists and neurosurgeons, along with treatments like multi-vitamins, piracetam, and citicoline, his forgetfulness and behavioral issues persisted. At the time of consultation, he was on citicoline 1000 mg/day, piracetam 800 mg/day, and multi-vitamins. Cognitive assessments using Hindi mini-mental status examination (HMSE) and Addenbrooke's cognitive examination III (ACE-III) revealed scores of 19/30 and 61/100, respectively. He was diagnosed with "Mild neurocognitive disorder due to known physiological condition" and prescribed memantine (10 mg/day), donepezil (10 mg/day), escitalopram (5 mg/day), and quetiapine (25 mg/day). The placement of the anode was done over the left dorsolateral prefrontal cortex (DLPFC) and the cathode over the cerebellar vermis using 2.0 milliampere current with an offset of 0.1 milliamperes (mA) for 20 min. The patient received two sessions of tRNS in a day and 5 to 6 days in a week. At the end of ten sessions, his ACE-III score improved to 82/100, and the HMSE score reached 24/30. At the end of 20 sessions of tRNS over 10 days, it resulted in an ACE-III score of 84/100 and an HMSE score of 28/30. After 30 tRNS sessions, the ACE-III score increased to 86/100, while the HMSE score remained at 28/30. He was taking a longer time in completing the tasks during the initial assessment, which improved substantially later during the course of treatment. Cognitive enhancement strategies, such as trail-making tests and puzzle solving, were incorporated during tRNS and drug therapy. Follow-up after 2 weeks showed improved scores of HMSE (29/30) and ACE-III (90/100). Maintenance tRNS sessions were recommended for periodic cognitive evaluations. The cognitive domains affected more profoundly (as reflected in HMSE score) were time orientation, concentration, and recent memory (registration and recall), following sequence of commands. The improvement in total HMSE score following intervention occurred due to improvement in those domains.

Our patient had prominent cognitive symptoms that were interfering with day-to-day functioning. The impairments mostly affected the memory, attention, and concentration domain. He was also...


Language: en

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print